SEC Form 13F
| Report period | 2026-06-30 |
|---|---|
| Publicly available | 2026-08-15 |
| Reported value | $1,639,957,110 |
| Positions | 37 |
| Issuer | Ticker | Class | Reported value | Reported amount |
|---|---|---|---|---|
| Cullinan Therapeutics, Inc. | CGEM | 230031106 | $177,207,720 | 9,731,341 |
| Aktis Oncology, Inc. | AKTS | 01021M104 | $155,860,155 | 4,835,872 |
| Liquidia Corporation | LQDA | 53635D202 | $110,519,653 | 1,386,174 |
| Revolution Medicines, Inc. | RVMD | 76155X100 | $92,232,216 | 492,483 |
| Corcept Therapeutics, Inc. | CORT | 218352102 | $67,040,885 | 771,028 |
| Edgewise Therapeutics Inc | EWTX | 28036F105 | $65,852,291 | 1,620,780 |
| Travere Therapeutics Inc | TVTX | 89422G107 | $63,782,348 | 1,122,731 |
| DBV Technologies S A | DBVT | 23306J309 | $60,127,058 | 3,666,284 |
| Trevi Therapeutics Inc | TRVI | 89532M101 | $57,322,211 | 3,073,577 |
| Alumis Inc | ALMS | 022307102 | $56,815,223 | 2,019,020 |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.